Oritavancin API Manufacturers

compare suppliers & get competitive offers

To view suppliers for this material, you need to be logged in first.

This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.

Looking for Oritavancin API 171099-57-3?

Description:: Here you will find a list of producers, manufacturers and traders of Oritavancin. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:: Oritavancin
Synonyms:: Chlorobiphenyl-chloroeremomycin
Cas Number:: 171099-57-3
DrugBank number:: DB04911
Unique Ingredient Identifier:: PUG62FRZ2E

About Oritavancin

Why are professionals looking for Oritavancin? Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat resistant Staphylococcus, Streptococcus, and other gram-positive bacteria that cause skin infections. It boasts the option of single-dose administration that has been proven as non-inferior to a full course of vancomycin therapy.

Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.

Oritavancin is a type of Glycopeptides

Glycopeptides are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the field of medicinal chemistry and drug development. These complex molecules consist of a peptide chain with one or more attached carbohydrate chains, known as glycans.

Glycopeptides possess unique chemical and structural properties that contribute to their diverse biological activities. They are primarily recognized for their potent antimicrobial properties and are commonly used to combat various bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant strains. This makes them highly valuable in the pharmaceutical industry.

The glycan moieties present in glycopeptides contribute to their mode of action. These carbohydrates aid in the recognition and binding of the glycopeptides to specific bacterial targets, inhibiting cell wall synthesis and disrupting bacterial growth. This mechanism of action sets glycopeptides apart from other classes of antibiotics, making them effective against resistant bacterial strains.

Glycopeptides can be produced through synthetic or semi-synthetic methods, with natural sources such as soil bacteria serving as starting materials. Vancomycin and teicoplanin are examples of well-known glycopeptide antibiotics. Researchers continue to explore the potential of glycopeptides in areas beyond antimicrobial applications, including cancer therapy and drug delivery systems.

In summary, glycopeptides represent a vital subcategory of pharmaceutical APIs with exceptional antimicrobial properties and significant potential in various therapeutic applications. Their complex structure and unique mechanism of action make them valuable assets in the fight against drug-resistant bacteria and other diseases.

Oritavancin (Glycopeptides), classified under Antibacterials

Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.

Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.

Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.

The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.

As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.

In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.